Taletrectinib promotes pyroptosis in colorectal carcinoma via SRC/AKT/mTOR axis inhibition
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-02901-3
Abstract: Drug resistance develops frequently after colorectal carcinoma (CRC) surgery, indicating the urgent need for new therapeutic strategies. Taletrectinib (DS-6051b/AB-106), a synthetic ROS1/NTRK inhibitor which has shown meaningful antitumor activity, is currently undergoing clinical trials aimed… read more here.
Keywords: src akt; via src; taletrectinib; crc ... See more keywords
Abstract 5612: Taletrectinib, a next generation selective ROS1 inhibitor, inhibits growth of ROS1 wild-type and ROS1-G2032R xenografts
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-5612
Abstract: The ROS1 gene is altered in approximately 2% of non-small cell lung cancer (NSCLC) patients. ROS1 fusions demonstrate ligand independent activity driving cell growth and survival. While several inhibitors for ROS1 have been FDA approved,… read more here.
Keywords: taletrectinib; wild type; ros1 g2032r; ros1 ... See more keywords
Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco-25-00275
Abstract: PURPOSE Taletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI). We report integrated efficacy and safety from registrational taletrectinib studies in ROS1+ non–small cell lung cancer. METHODS TRUST-I and TRUST-II were… read more here.
Keywords: non small; taletrectinib; cell lung; small cell ... See more keywords